Lung cancer: A review

American Journal of Health-System Pharmacy

Volumn 59, Issue 7, 2002, Pages 611-642

  Cersosimo, Robert J ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

Author keywords

Antineoplastic agents; Carboplatin; Cisplatin; Combined therapy; Docetaxel; Gemcitabine; Irinotecan; Lung neoplasms; Paclitaxel; Rational therapy; Surgery; Topotecan; Vinorelbine

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FOLINIC ACID; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; METHOTREXATE; NAVELBINE; PACLITAXEL; PLATINUM; TOPOTECAN; VINBLASTINE; VINCRISTINE;

CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; FEMALE; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; MALE; MEDIASTINUM LYMPH NODE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SIDE EFFECT; SMOKING; SYMPTOMATOLOGY;

EID: 0036534123     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/59.7.611     Document Type: Review

References (303)

1. Cancer statistics, 2001
2. Annual report to the nation on the status of cancer 1973-1996 with a special section on lung cancer and tobacco smoking
3. Cigarette smoking among adults - United States, 1995
4. Mortality in relation to smoking: 20 years' observations on male British doctors
5. Smoking and lung cancer in women: Findings in a prospective study
6. Does breathing other people's smoke cause lung cancer?
7. A case-referent study of lung cancer, occupational exposure, and smoking II: Role of asbestos exposure
8. Contribution of environmental fibres to respiratory cancer
9. Non-small cell lung cancer
10. 1 antitrypsin deficiency allele carriers among lung cancer patients
11. The natural history of lung cancer: A review based on rates of tumour growth
12. Revisions in the international system for staging lung cancer
13. Staging and prognostic factors in small cell carcinoma of the lung
14. Modern 30-day operative mortality for surgical resection in lung cancer
15. Lung
16. Post-operative radiation therapy in lung cancer: A controlled trial after resection of curative design
17. Clinical trials in malignant disease: Part IV. Lung cancer: Value of post-operative radiotherapy
18. Effects of postoperative mediastinal radiation on completely resected stage II and stage III epidermoid cancer of the lung
19. The role of post-operative radiotherapy in non-small-cell lung cancer: A multicentre randomized trial in patients with pathologically staged T 1-2, N 1-2, M 0 disease
20. Postoperative radiotherapy in non-small cell lung cancer: Systematic review and meta-analysis of individual patient data from nine randomised controlled trials
21. Adjuvant chemotherapy in non-small cell lung cancer
22. Chest wall invasion in carcinoma of the lung. Therapeutic and prognostic implications
23. Bronchogenic carcinoma with chest wall invasion: Factors affecting survival following en bloc resection
24. Review of the curative role of radiotherapy in the treatment of non-small cell lung cancer
25. Long-term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy. Report of the Radiation Therapy Oncology Group
26. Combined radiotherapy and chemotherapy with cyclophosphamide, Adriamycin, methotrexate, procarbazine (CAMP) in 64 consecutive patients with epidermoid bronchogenic carcinoma, limited disease: A prospective study
27. Thoracic radiation therapy and Adriamycin/cisplatin-containing chemotherapy for locally advanced non-small-cell lung cancer
28. Inoperable non-small cell lung cancer: Radiation with or without chemotherapy
29. Thoracic radiation therapy alone compared with combined chemotherapy for locally unresectable non-small cell lung cancer. A randomized Phase III trial
30. Radiotherapy alone versus combined chemotherapy and radiotherapy in non-resectable non-small cell lung cancer: First analysis of a randomized trial in 353 patients
31. Improved survival in stage III non-small-cell lung cancer: Seven-year follow-up of Cancer and Leukemia Group B (CALGB) 8433 trial
32. A randomized study of high-dose split course radiotherapy preceded by high-dose chemotherapy versus high-dose radiotherapy only in locally advanced non-small-cell lung cancer
33. Final results of Phase III trial in regionally advanced unresectable non-small cell lung cancer
34. A randomized clinical trial comparing radiation therapy v radiation therapy plus cis-dichlorodiammine platinum (II) in the treatment of locally advanced non-small cell lung cancer
35. Thoracic radiotherapy does not prolong survival in patients with locally advanced, unresectable non-small cell lung cancer
36. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer
37. Radical radiotherapy and chemotherapy in localized inoperable non-small-cell lung cancer: A randomized trial
38. Phase III trial of thoracic irradiation with or without cisplatin for locally advanced unresectable non-small-cell lung cancer: A Hoosier oncology group protocol
39. Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer: A randomized study
40. Phase III study of concurrent vs. sequential thoracic radiotherapy (TRT) in combination with mitomycin (M), vindesine (V), and cisplatin (P) in unresectable stage III non-small cell lung cancer (NSCLC): Five-year median follow-up results
41. Phase III comparison of sequential vs concurrent chemoradiation for patients (pts) with unresected stage III non-small cell lung cancer (NSCLC): Initial report of Radiation Therapy Oncology Group (RTOG) 9410
42. Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer
43. NCCN non-small-cell-lung cancer practice guidelines
44. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small cell lung cancer
45. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage I-IIIA non-small-cell lung cancer
46. Survival of patients with resected N2 non-small-cell lung cancer: Evidence for a subclassification and implications
47. Phase III trial of neo-adjuvant chemotherapy (NCT) in resectable stage I (except T1N0), II, IIIA non-small-cell lung cancer (NSCLC): The French experience
48. Chemotherapy vs supportive care in advanced non-small cell lung cancer. Results of a meta-analysis of the literature
49. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized clinical trials. Non-small cell lung cancer collaborative group
50. Single agent versus combination chemotherapy in patients with advanced non-small cell lung carcinoma. A meta-analysis of response, toxicity, and survival
51. Chemotherapy for advanced non-small cell lung cancer
52. Chemotherapy for non-small cell lung cancer: Have we reached a new plateau?
53. Combination chemotherapy with cisplatin and etoposide in bronchogenic squamous cell carcinoma and adenocarcinoma
54. Carboplatin and etoposide in an outpatient schedule for the palliation of advanced non-small-cell lung cancer
55. Carboplatin and etoposide as outpatient treatment of advanced non-small-cell lung cancer
56. Intensive etoposide and carboplatin chemotherapy for advanced non-small-cell lung cancer. A Phase II trial of the Cancer and Leukemia Group B
57. A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: EORTC protocol 07861
58. Phase II study of Taxol in patients with stage IV non-small cell lung cancer (NSCLC). The Eastern Cooperative Oncology Group (ECOG) results
59. Phase II study of Taxol in patients with untreated advanced non-small cell lung cancer
60. Phase II trial of a 3-hour infusion of paclitaxel in previously untreated patients with advanced non-small cell lung cancer
61. Phase II study of 3-hour infusion of paclitaxel in previously untreated non-small cell lung cancer
62. Phase II study of 3-hour infusion of paclitaxel in patients with previously untreated stage III and IV non-small cell lung cancer
63. Weekly paclitaxel in patients with advanced lung cancer: Preliminary data from a Phase II trial
64. Chemotherapy of advanced inoperable non-small cell lung cancer with paclitaxel: A Phase II trial
65. Paclitaxel by 1-hour infusion: An active drug in metastatic non-small-cell lung cancer
66. Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer
67. Comparison of survival and quality of life in advanced non-small cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: Results of an eastern cooperative oncology group trial
68. Paclitaxel and cisplatin in patients with non-small cell lung cancer: Results of a Phase II trial
69. Paclitaxel/cisplatin in advanced non-small cell lung cancer (NSCLC)
70. Phase I-II trial of paclitaxel (Taxol) and cisplatin in previously untreated advanced non-small cell lung cancer (NSCLC)
71. Preliminary results of a Phase II study of paclitaxel and cisplatin in patients with non-small cell lung cancer
72. Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small cell lung cancer
73. Treatment with paclitaxel 1-hour infusion and carboplatin of patients with advanced non-small-cell lung cancer: A Phase II multicentre trial
74. Phase II trial of paclitaxel and carboplatin as first-line treatment in advanced non-small cell lung cancer (NSCLC)
75. Paclitaxel by either 1-hour or 24-hour infusion in combination with carboplatin in advanced non-small cell lung cancer: Preliminary results comparing sequential Phase II trials
76. One-hour paclitaxel plus carboplatin for advanced non-small-cell lung cancer
77. Phase II study of paclitaxel and carboplatin for advanced non-small cell lung cancer
78. Phase II study of a one hour paclitaxel infusion in combination with carboplatin in advanced non-small cell lung cancer
79. Paclitaxel 3-hour infusion given alone and combined with carboplatin: Preliminary results of dose-escalation trials
80. Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: A Phase II toxicity, response, and survival analysis
81. Paclitaxel plus carboplatin in advanced non-small-cell lung cancer: A Phase II trial
82. Paclitaxel (1-hour) and carboplatin (area under the concentration-time curve 7.5) in advanced non-small cell lung cancer: A Phase II study of the Fox Chase Cancer Center and its network
83. Combination chemotherapy with paclitaxel plus carboplatin versus paclitaxel plus gemcitabine in inoperable non-small cell lung cancer: A Phase III randomized study. Preliminary results
84. Phase II trial of docetaxel in previously untreated advanced non-small cell lung cancer: A Japanese cooperative study
85. 2 dose of doce-taxel with prednisone pre-medication for patients with advanced non-small cell lung cancer
86. Docetaxel (Taxotere) is active in non-small cell lung cancer: A Phase II trial of the EORTC early clinical trials group (ECTG)
87. Phase II trial of docetaxel in Asian patients with inoperable stage III non-small cell lung cancer
88. A multicenter, randomized, Phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC)
89. Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer
90. Phase II study of docetaxel for recurrent or metastatic non-small cell lung cancer
91. Phase II study of docetaxel (Taxotere) in first- and second-line NSCLC
92. Phase-II trial of Taxotere (docetaxel) in advanced non-small cell lung cancer
93. Phase II trial of docetaxel with dexamethasone premedication in patients with advanced non-small cell lung cancer: The Canadian experience
94. Interim results of a Phase II study of docetaxel (Taxotere) in unresectable non-small cell lung cancer (NSCLC) on 204 chemotherapy naive or pretreated patients
95. Weekly docetaxel in the treatment of elderly patients with advanced nonsmall cell lung carcinoma. A Minnie pearl cancer network Phase II trial
96. Phase I-II study of cisplatin + docetaxel (Taxotere) in non-small cell lung cancer (NSCLC)
97. Multicenter Phase II trial of docetaxel and cisplatin combination in patients with non-small cell lung cancer
98. Phase II study of docetaxel and cisplatin in advanced non-small-cell lung cancer
99. Docetaxel (Taxotere) plus cisplatin an active well-tolerated combination in patients with advanced non-small cell lung cancer
100. First-line treatment of advanced non-small-cell lung cancer with docetaxel and cisplatin: A multicenter Phase II study
101. Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer
102. Activity of docetaxel in platinum-treated non-small-cell lung cancer: Results of a Phase II multi-center trial
103. Randomized Phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens
104. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy
105. Docetaxel (Taxotere) administered in weekly schedules
106. Weekly docetaxel as a single agent and in combination with gemcitabine in elderly and poor performance status patients with advanced non-small cell lung cancer
107. Phase II trial of weekly docetaxel (D) in second-line non-small cell lung cancer (NSCLC)
108. Weekly docetaxel as second line therapy of advanced non small cell lung cancer (NSCLC): A preliminary feasibility report
109. Early Phase II of docetaxel in second line of advanced non-small cell lung cancer (NSCLC): Preliminary results
110. Gemcitabine monotherapy in elderly patients with advanced non-small cell lung cancer: A multicenter Phase II study
111. Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: A Phase II study
112. Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: A Phase II study
113. Phase II study of weekly gemcitabine in advanced non-small cell lung cancer
114. Initial experience with gemcitabine for non-small cell lung cancer (NSCLC) in Australia
115. Activity of gemcitabine in patients with non-small cell lung cancer: A multicentre, extended Phase II study
116. Phase II studies of gemcitabine for non-small cell lung cancer in Japan
117. Single-agent gemcitabine versus cisplatin-etoposide: Early results of a randomized Phase II study in locally advanced or metastatic non-small-cell lung cancer
118. Gemcitabine versus the combination of cisplatin and etoposide in patients with inoperable non-small-cell lung cancer in a Phase II randomized study
119. Weekly gemcitabine and monthly cisplatin for advanced non-small cell lung carcinoma
120. Phase II trial of gemcitabine plus cisplatin in non-small cell lung cancer: A Hoosier oncology group study
121. Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: A Phase II study
122. Phase I/II study of gemcitabine and cisplatin in the treatment of advanced non-small cell lung cancer: Preliminary results
123. Phase II trial assessing the combination of gemcitabine and cisplatin in advanced non-small cell lung cancer (NSCLC)
124. Phase II trial of gemcitabine and weekly cisplatin for advanced non-small cell lung cancer
125. Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer - A randomized trial with quality of life as the primary outcome
126. Phase II trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer
127. Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: A randomized Phase III study of the Italian Lung Cancer Project
128. Randomized Phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer
129. Combination chemotherapy with paclitaxel plus carboplatin versus paclitaxel plus gemcitabine in inoperable non-small cell lung cancer: A Phase III randomized study, preliminary results
130. A Phase II study of gemcitabine plus carboplatin in chemonaive patients with advanced non-small cell lung cancer (NSCLC)
131. Combination of gemcitabine (gem) and carboplatin (carbo) as first line treatment in non-small cell lung cancer (NSCLC)
132. Phase I-II study of gemcitabine and carboplatin in stage IIIb-IV non-small cell lung cancer
133. A combination therapy of gemcitabine (GEM) and carboplatin (CBDCA) in advanced stage non-small cell lung carcinoma (NSCLC)
134. Gemcitabine and carboplatinum in advanced non-small cell lung carcinoma; results of single institution Phase II study
135. First-line therapy with gemcitabine (Gemtro) (G) and carboplatin (C) in patients (pts) with advanced non-small cell lung cancer (NSCLC): A Phase II study
136. Phase II trial of gemcitabine and carboplatin in advanced non-small cell lung cancer
137. Weekly vinorelbine in elderly patients with non-small-cell lung cancer
138. Multi-institutional Phase II study of Navelbine (vinorelbine) in non-small cell lung cancer
139. Vinorelbine treatment of advanced non-small cell lung cancer with special emphasis on elderly patients
140. Vinorelbine is well tolerated and active in the treatment of elderly patients with advanced non-small cell lung cancer, a two-stage Phase II study
141. A Phase II study of Navelbine (vinorelbine) in the treatment of non-small-cell lung cancer
142. Non-small cell lung cancer treatment with vinorelbine monochemotherapy: A Phase II study
143. Vinorelbine chemotherapy in non small cell lung cancer: Experience in elderly patients
144. Preliminary results of a Phase II trial of biweekly vinorelbine as a single-agent in non-small cell lung cancer (NSCLC)
145. Vinorelbine versus vinorelbine plus cisplatin in advanced non-small cell lung cancer: A randomized trial
146. Randomized study of vinorelbine (VRB) versus vindesine (VDS) in previously untreated stage IIIb or IV non-small cell lung cancer (NSCLC)
147. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: Results of a European multicenter trial including 612 patients
148. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small cell lung cancer
149. Randomized trial comparing cisplatin, gemcitabine, and vinorelbine with either cisplatin and gemcitabine, or cisplatin and vinorelbine in advanced non-small cell lung cancer: Interim analysis of a Phase III trial of the Southern Italy Cooperative Oncology Group
150. A Phase II trial of vinorelbine and cisplatin in previously untreated inoperable non-small-cell lung cancer
151. Phase II trial of i.v. vinorelbine and cisplatin in inoperable locally advanced or disseminated non-small-cell lung cancer: The South African experience
152. Phase I-II study of vinorelbine (Navelbine) plus cisplatin in advanced non-small cell lung cancer
153. Vinorelbine plus cisplatinum for the treatment of stage IIIb and IV non small cell lung carcinoma
154. Vinorelbine and cisplatin in the treatment of advanced non-small cell lung cancer: Results of a multicenter Czech study
155. Cisplatin-vinorelbine combination chemotherapy in locally advanced non-small cell lung cancer
156. Multicenter Phase II trial of intermediate dose cisplatin and vinorelbine in inoperable non-small cell lung cancer patients
157. Phase III study of Navelbine (NVB) vs. NVB plus cisplatin in non small cell lung cancer (NSCLC) stage IIIb or IV
158. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small cell lung cancer: A Southwest Oncology Group study
159. Multicenter randomized clinical trial on high-dose epirubicin plus cisplatinum versus vinorelbine plus cisplatinum in advanced non small cell lung cancer
160. A randomized Phase III trial of paclitaxel plus carboplatin (PC) versus vinorelbine plus cisplatin (VC) in untreated advanced non-small cell lung cancer (NSCLC): A Southwest Oncology Group (SWOG) trial
161. Gemcitabine plus vinorelbine in non small cell lung carcinoma patients age 70 years or older or patients who cannot receive cisplatin
162. Phase II study of vinorelbine and gemcitabine for inoperable stage IIIb-IV non small-cell lung cancer
163. Gemcitabine and vinorelbine in advanced nonsmall cell lung cancer
164. Gemcitabine plus vinorelbine as first-line chemotherapy in advanced nonsmall cell lung carcinoma, a Phase II trial
165. Gemcitabine plus vinorelbine in elderly or unfit patients with non-small cell lung cancer
166. Phase II study of gemcitabine (GEM) plus Navelbine (NVB) in previously untreated stage III or IV non-small cell lung cancer (NSCLC)
167. Gemcitabine and vinorelbine in advanced non-small cell lung cancer
168. A multicenter Phase II trial with gemcitabine (GEM) and vinorelbine (VNR) in the treatment of non-small cell lung cancer (NSCLC) stage IIIb and IV
169. Vinorelbine/gemcitabine in advanced non-small-cell lung cancer (NSCLC): An AASLC Phase II trial
170. A multi-center Phase II study of gemcitabine (GEM) and vinorelbine (VNR) in patients with advanced stage IIIb-IV non-small cell lung cancer
171. Ifosfamide and vinorelbine as first-line chemotherapy for advanced non-small cell lung carcinoma
172. Vinorelbine and ifosfamide for unresectable non-small cell lung cancer
173. First-line treatment of advanced non small cell lung carcinoma with docetaxel and vinorelbine
174. Phase II trial of docetaxel and vinorelbine in patients with advanced non-small-cell lung cancer
175. A Phase II study of docetaxel and vinorelbine combination chemotherapy in patients with advanced non-small cell lung cancer
176. Efficacy and toxicity of vinorelbine-carboplatin combination in the treatment of advanced adenocarcinoma or large-cell carcinoma of the lung
177. Carboplatin and vinorelbine in the treatment of advanced non-small-cell lung cancer. A multicenter Phase II study
178. Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer
179. A Phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer
180. A Phase II study of CPT-11, a camptothecin derivative, in patients with primary lung cancer
181. Phase II study of irinotecan (CPT-11) in advanced non-small cell lung cancer (NSCLC)
182. Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy
183. A Phase II trial of combination of CPT-11 and cisplatin for advanced non-small-cell lung cancer
184. A Phase II study of irinotecan and infusional cisplatin with recombinant human granulocyte colony-stimulating factor support for advanced non-small-cell lung cancer
185. Gemcitabine, ifosfamide, cisplatin (GIP) for the treatment of stage IIIb-IV non small cell lung cancer (NSCLC): A Phase II study of the Italian Oncology Group for clinical research
186. A Phase II trial of the combination of gemcitabine, ifosfamide, and cisplatin in the treatment of advanced non small cell lung cancer
187. Gemcitabine, ifosfamide, and platin in non-small cell lung cancer (NSCLC): An intention-to-treat Phase II "EOLO" study
188. Gemcitabine (GEM) in combination with ifosfamide (IFO) and cisplatin (CDDP) in advanced non-small cell lung cancer (NSCLC), a Phase II study
189. Cisplatin, gemcitabine, and vinorelbine in locally advanced or metastatic non-small-cell lung cancer: A Phase I study
190. A Phase II study of gemcitabine, cisplatin, and vinorelbine in patients with advanced non-small cell lung cancer (NSCLC)
191. A Phase II study of gemcitabine, cisplatin, and vinorelbine in patients with advanced non-small cell lung cancer (NSCLC)
192. A Phase II study of vinorelbine, gemcitabine, and cisplatin in the treatment of patients with stage IIIb-IV non-small cell lung cancer (NSCLC)
193. Cisplatin, gemcitabine, and vinorelbine combination therapy in advanced non-small-cell lung cancer: A Phase II randomized study of the Southern Italy Cooperative Oncology Group
194. Gemcitabine-cisplatin-vinorelbine Phase II trial in stage II non small cell lung cancer
195. Vinorelbine, ifosfamide, and cisplatin in advanced non small cell lung cancer
196. Cisplatin, ifosfamide, and vinorelbine in combination chemotherapy in stage III-IV non-small-cell lung cancer. A Phase II study
197. Cisplatin-vindesine-mitomycin (MVP) vs cisplatin-ifosfamide-vinorelbine (PIN) vs carboplatin-vinorelbine (CaN) in patients with advanced non-small-cell lung cancer (NSCLC): A Fonicap randomized Phase II study
198. Phase II study of vinorelbine/ifosfamide/cisplatin for the treatment of advanced non-small-cell lung cancer
199. Cisplatin and ifosfamide with various doses of vinorelbine (Navelbine) in advanced non-small cell lung cancer
200. Vinorelbine and alternating cisplatin and ifosfamide in the treatment of non-small cell lung cancer
201. A Phase II trial of vinorelbine (V), ifosfamide (I), and cisplatin (P) (VIP) in patients with previously untreated advanced non-small cell lung cancer (NSCLC)
202. Duration of chemotherapy in advanced non-small cell lung cancer: A randomized trial of three vs. six courses of mitomycin, vinblastine, and cisplatin
203. Chemotherapy of lung cancer
204. Initial therapy with cisplatin plus VP-16 in small cell lung cancer
205. VP-16 and carboplatin in previously untreated patients with extensive small cell lung cancer: A study of the National Cancer Institute of Canada Clinical Trials Group
206. Carboplatin (Paraplatin, JM8) and etoposide (VP-16) as first-line combination treatment for small-cell lung cancer
207. Carboplatin/etoposide in small cell lung cancer
208. Phase I/II trial of etoposide and carboplatin in extensive small-cell lung cancer, a report from the Cancer and Leukemia Group B
209. Treatment of SCLC chemotherapy
210. Carboplatin, etoposide, and vincristine (CEV) plus/minus GM-CSF in the treatment of small cell lung cancer (SCLC): A Phase II study
211. Combination chemotherapy with carboplatin, etoposide, and vincristine as first-line treatment in small-cell lung cancer
212. Cyclophosphamide, doxorubicin, and etoposide as first-line therapy in the treatment of small-cell lung cancer
213. Addition of etoposide to cyclophosphamide, doxorubicin, and vincristine for remission induction and survival in patients with small cell lung cancer
214. Treatment of limited-stage small-cell lung cancer with cyclophosphamide, doxorubicin, and vincristine with or without etoposide: A randomized trial of the North Central Cancer Treatment Group
215. Phase II study of an intensive combination chemotherapy with cisplatin, Adriamycin, etoposide, and cyclophosphamide (CAVE) in small cell lung cancer
216. CODE chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer
217. Randomized study of CODE versus alternating CAV/EP for extensive-stage small cell lung cancer: An intergroup study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group
218. Carboplatin, etoposide, and ifosfamide as intensive chemotherapy for small cell lung cancer
219. Phase II study of ifosfamide, carboplatin, and oral etoposide chemotherapy for extensive-stage small-cell lung cancer: An Eastern Cooperative Oncology Group pilot study
220. Etoposide, ifosfamide, and cisplatin in extensive small cell lung cancer
221. A Phase II study of ifosfamide in combination with etoposide and cisplatin in the treatment of extensive small cell lung cancer
222. Superiority of alternating non-cross resistant chemotherapy in extensive small cell lung cancer. A multicenter, randomized trial by the National Cancer Institute of Canada
223. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer
224. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small cell lung cancer: A Phase III trial of the Southwest Cancer Study Group
225. Small cell lung cancer
226. Chemotherapy alone or chemotherapy with chest radiation therapy in limited stage small cell lung cancer. A prospective, randomized trial
227. Chemotherapy with or without radiation therapy in limited small-cell carcinoma of the lung
228. A randomized study of radiation treatment in small cell bronchial carcinoma treated with 2 types of four-drug chemotherapy regimens
229. Combination chemotherapy with or without consolidation radiation therapy (RT) for regional small cell carcinoma of the lung
230. Late consolidation radiation therapy in the treatment of limited-stage small cell lung cancer
231. Does thoracic irradiation improve survival and local control in limited stage small cell carcinoma of the lung? A meta-analysis
232. A meta-analysis of thoracic radiotherapy for small cell lung cancer
233. Importance of timing for therapeutic irradiation in the combined modality treatment of limited-stage small-cell lung cancer
234. Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited small cell lung cancer: A randomized study
235. The relationship between thoracic irradiation timing and long-term survival in combined modality therapy of limited stage small cell lung cancer (LSCLC)
236. Carboplatin: A very active new cisplatin analog in the treatment of small cell lung cancer
237. A Phase II trial of carboplatin in untreated patients with extensive stage small cell lung cancer
238. Cisplatin/etoposide versus carboplatin/etoposide chemotherapy and irradiation in small cell lung cancer. A randomized Phase III study
239. Activity of docetaxel (Taxotere) in small cell lung cancer
240. Evaluation of docetaxel in previously untreated extensive-stage small cell lung cancer: A Southwest Oncology Group Phase II trial
241. A Phase II study of paclitaxel in heavily pre-treated patients with small-cell lung cancer
242. Phase II study of paclitaxel in patients with extensive-disease small-cell lung cancer: An Eastern Cooperative Oncology Group study
243. Paclitaxel and GC-SF in previously untreated patients with extensive stage small-cell lung cancer
244. Phase II study of CPT-11, new camptothecin derivative in small cell lung cancer (SLC)
245. CPT-11: A new derivative of camptothecin for the treatment of refractory or relapsed small cell lung cancer
246. A Phase II study of irinotecan (CPT-11) in patients (pts) with small cell lung cancer (SCLC) progressing after initial response to first-line chemotherapy (CT)
247. Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: An Eastern Cooperative Oncology Group trial
248. Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan
249. Topotecan in second-line treatment of small cell lung cancer-reduced toxicity and individualized therapy
250. Topotecan, a new active drug in the second-line treatment of small cell lung cancer: A Phase II study in patients with refractory and sensitive disease
251. Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: An Eastern Cooperative Oncology Group trial
252. Topotecan (T) as second-line therapy in patients (pts) with small cell lung cancer (SCLC): A Phase II study
253. Topotecan (Hycamtin) in small cell lung cancer after failure of first line therapy: Multicentre Phase II study
254. Evaluation of topotecan (Hycamtin) in relapsed small cell lung cancer (SCLC), a multicentre Phase II study
255. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer
256. Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer (SCLC). A study of the National Cancer Institute of Canada Clinical Trials Group
257. Phase II study of Navelbine (NVB) in small cell lung cancer (SCLC)
258. Phase II study of vinorelbine (Navelbine) in previously treated small cell lung cancer patients
259. Phase II trial of Navelbine (NVB) in relapsed small cell lung cancer
260. Phase II study of vinorelbine in heavily pre-treated small cell lung cancer
261. Carboplatin plus vinorelbine, a new well-tolerated and active regimen for the treatment of extensive-stage small cell lung cancer: A Phase II study
262. Paclitaxel and carboplatin in the treatment of small-cell lung cancer patients resistant to cyclophosphamide, doxorubicin, and etoposide: A non-cross-resistant schedule
263. A Phase II study of paclitaxel (Taxol) and cisplatin (CDDP) in the treatment of extensive stage small cell lung cancer (ESSCLC)
264. Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer
265. Combination chemotherapy with cisplatin and topotecan as second-line treatment of sensitive (S) and refractory (R) small cell lung cancer (SCLC): An EORTC LCCG Phase II study
266. Paclitaxel, carboplatin, and extended schedule etoposide in the treatment of small cell lung cancer: Comparison of sequential Phase II trials using different dose-intensities
267. Paclitaxel, carboplatin, and oral etoposide: A Phase II trial in limited-stage small cell lung cancer
268. Cisplatin, etoposide, and paclitaxel in the treatment of patients with extensive small-cell carcinoma of the lung
269. Co-trimoxazole prophylaxis during high-dose chemotherapy of small-cell lung cancer
270. A randomized comparison of high-dose versus conventional-dose cyclophosphamide, doxorubicin, and vincristine for extensive-stage small-cell lung cancer: A Phase III trial of the Southeastern Cancer Study Group
271. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small cell lung cancer
272. Dose-intensity of a four-drug chemotherapy regimen with or without recombinant human granulocyte-macrophage colony stimulating factor in extensive-stage small cell lung cancer: A multicenter randomized Phase III study
273. Intensive weekly chemotherapy for the treatment of extensive-stage small cell lung cancer
274. Multiple-drug weekly chemotherapy versus standard combination regimen in small cell lung cancer: A Phase III randomized study conducted by the European Lung Cancer Working Party
275. Randomized trial comparing weekly versus 3-week chemotherapy in small-cell lung cancer: A Cancer Research Campaign trial
276. Phase III study of dose intensive weekly chemotherapy with recombinant human granulocyte-colony stimulating factor (G-CSF) versus standard chemotherapy in extensive stage small cell lung cancer (SCLC)
277. Intensive weekly chemotherapy for good-prognosis patients with small-cell lung cancer
278. Treatment of small-cell lung cancer with an alternating chemotherapy regimen given at weekly intervals: A Southwest Oncology Group pilot study
279. Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony stimulating factor support: Results of a British Medical Research Council multicenter randomized trial
280. Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small-cell lung cancer: A prospective randomized study of 300 patients
281. Current management of small cell lung cancer
282. A randomized combined modality trial in small cell carcinoma of the lung
283. Maintenance chemotherapy for anaplastic small cell carcinoma of the bronchus: A randomized, controlled trial
284. Maintenance chemotherapy in limited small cell lung cancer: A randomized controlled clinical trial
285. Strategies to eradicate minimal residual disease in small cell lung cancer; high-dose chemotherapy with autologous bone marrow transplantation, matrix metalloproteinase inhibitors, and BEC2 plus BCG vaccinations
286. A Phase II study of oral etoposide in elderly patients with small cell lung cancer
287. Oral etoposide alone is inadequate palliative chemotherapy for small cell lung cancer: A randomized trial
288. Five-day oral etoposide treatment for advanced small-cell lung cancer: Randomized comparison with intravenous chemotherapy
289. Prophylactic cranial irradiation in small cell lung cancer: Rationale, results, and recommendations
290. Prophylactic cranial irradiation in small cell lung cancer - An update
291. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission
292. Economic issues in lung cancer: A review
293. An estimate of the cost effectiveness of gemcitabine in stage IV non-small cell lung cancer
294. Cost effectiveness of vinorelbine alone or vinorelbine plus cisplatin for stage IV NSCLC
295. Economic evaluation of randomized clinical trial comparing vinorelbine, vinorelbine plus cisplatin, and vindesine plus cisplatin for non-small-cell lung cancer
296. Vinorelbine in advanced non-small cell lung cancer. A pharmacoeconomic review
297. Decision framework for chemotherapeutic interventions for metastatic non-small-cell lung cancer